AR033059A1 - Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada. - Google Patents

Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.

Info

Publication number
AR033059A1
AR033059A1 ARP020101020A ARP020101020A AR033059A1 AR 033059 A1 AR033059 A1 AR 033059A1 AR P020101020 A ARP020101020 A AR P020101020A AR P020101020 A ARP020101020 A AR P020101020A AR 033059 A1 AR033059 A1 AR 033059A1
Authority
AR
Argentina
Prior art keywords
zinc
insulin
poor
exempt
improved stability
Prior art date
Application number
ARP020101020A
Other languages
English (en)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of AR033059A1 publication Critical patent/AR033059A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulacion farmacéutica que contiene un polipéptido elegido de un grupo que contiene insulina, un metabolito de insulina, un análogo de insulina, un derivado de insulina o combinaciones de los mismos; un tensioactivo o combinacion de varios tensioactivos; opcionalmente, un agente conservante o combinaciones de varios agentes conservantes; y, opcionalmente, un agente isotonico, tampon u otros coadyuvantes o combinaciones de los mismos, estando la formulacion farmacéutica de zinc o siendo pobre en zinc; y a la produccion de preparados de insulina de este tipo.
ARP020101020A 2001-03-23 2002-03-21 Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada. AR033059A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10114178A DE10114178A1 (de) 2001-03-23 2001-03-23 Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität

Publications (1)

Publication Number Publication Date
AR033059A1 true AR033059A1 (es) 2003-12-03

Family

ID=7678654

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP020101020A AR033059A1 (es) 2001-03-23 2002-03-21 Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
ARP140102020A AR096376A2 (es) 2001-03-23 2014-05-21 Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140102020A AR096376A2 (es) 2001-03-23 2014-05-21 Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada

Country Status (32)

Country Link
US (5) US6960561B2 (es)
EP (2) EP2289539B1 (es)
JP (1) JP4231292B2 (es)
KR (2) KR100987311B1 (es)
CN (1) CN1273187C (es)
AR (2) AR033059A1 (es)
AT (1) ATE497777T1 (es)
AU (1) AU2002302409B2 (es)
BR (1) BRPI0208210B8 (es)
CA (1) CA2441260C (es)
CY (2) CY1111413T1 (es)
DE (2) DE10114178A1 (es)
DK (2) DK1381385T3 (es)
ES (2) ES2393180T3 (es)
HK (1) HK1061521A1 (es)
HR (1) HRP20030765B1 (es)
HU (1) HU228847B1 (es)
IL (2) IL158057A0 (es)
ME (1) ME00408B (es)
MX (1) MXPA03007942A (es)
MY (1) MY129417A (es)
NO (1) NO326780B1 (es)
NZ (1) NZ528335A (es)
PE (1) PE20020968A1 (es)
PL (1) PL205465B1 (es)
PT (2) PT2289539E (es)
RS (1) RS51579B (es)
RU (1) RU2311922C2 (es)
SI (1) SI1381385T1 (es)
TW (1) TWI301761B (es)
WO (1) WO2002076495A1 (es)
ZA (1) ZA200306637B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL131796A0 (en) * 1997-03-20 2001-03-19 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20050250676A1 (en) * 2001-11-19 2005-11-10 Aventis Pharma Deutschland Gmbh Method of activating insulin receptor substrate-2 to stimulate insulin production
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DE10250297A1 (de) * 2002-10-29 2004-05-19 Aventis Pharma Deutschland Gmbh Kristalle von Insulinanaloga und Verfahren zu ihrer Herstellung
US7193035B2 (en) 2002-10-29 2007-03-20 Sanofi-Aventis Deutschland Gmbh Crystals of insulin analogs and processes for their preparation
WO2004096266A1 (en) * 2003-05-02 2004-11-11 Novo Nordisk A/S Improved physical stability of insulin formulations
EP1660531A2 (en) 2003-08-05 2006-05-31 Novo Nordisk A/S Novel insulin derivatives
JP4601627B2 (ja) * 2004-01-16 2010-12-22 バイオデル， インコーポレイテッド 舌下薬物送達デバイス
DE602005021756D1 (de) * 2004-02-13 2010-07-22 Nod Pharmaceuticals Inc Partikel mit kern aus calciumphosphat-nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
PT1740154E (pt) * 2004-03-12 2009-09-11 Biodel Inc Composições de insulina com absorção melhorada
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
EP2626368B1 (en) 2004-07-19 2016-12-21 Biocon Limited Insulin-oligomer conjugates, formulations and uses thereof
JP2006087815A (ja) * 2004-09-27 2006-04-06 Canon Inc 噴霧方法および該方法に基づく噴霧装置
US20060194762A1 (en) * 2004-12-23 2006-08-31 Olaf Reer Composition comprising an epothilone and methods for producing a composition comprising an epothilone
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
DK1969004T3 (da) * 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
JP2009533471A (ja) 2006-04-12 2009-09-17 バイオデル， インコーポレイテッド 即効型および長時間作用型組合せインスリン製剤
WO2007121318A2 (en) 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin
US7714025B2 (en) * 2006-05-10 2010-05-11 Arizona Biomedical Research Commission Modified chalcone compounds as antimitotic agents
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
US9034818B2 (en) 2007-06-13 2015-05-19 Novo Nordisk A/S Pharmaceutical formulations comprising an insulin derivative
WO2009065126A2 (en) * 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
US20090186819A1 (en) * 2007-12-11 2009-07-23 Marieve Carrier Formulation of insulinotropic peptide conjugates
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
KR101239008B1 (ko) * 2008-03-31 2013-03-04 한양대학교 산학협력단 바일산 유도체 및 그의 응용
JP2010063762A (ja) * 2008-09-12 2010-03-25 Yoshiharu Masui 抗菌消臭剤
LT2349324T (lt) 2008-10-17 2017-12-27 Sanofi-Aventis Deutschland Gmbh Insulino ir glp-1 agonisto derinys
CA2738615A1 (en) 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
US9060927B2 (en) 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
CN102470165B (zh) * 2009-06-26 2014-12-24 诺沃-诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂
MA33442B1 (fr) * 2009-07-06 2012-07-03 Sanofi Aventis Deutschland Préparations d'insuline contenant de la méthionine
PL2498801T3 (pl) 2009-11-13 2018-08-31 Sanofi Aventis Deutschland Kompozycja farmaceutyczna zawierająca desPro<sup>36</sup>eksendyno-4(1-39)-Lys6-NH2 i metioninę
ES2534191T3 (es) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
HUE031181T2 (en) 2010-08-30 2017-06-28 Sanofi Aventis Deutschland Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN108079281A (zh) 2011-08-29 2018-05-29 赛诺菲-安万特德国有限公司 用于2型糖尿病患者中的血糖控制的药物组合
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
KR20150021011A (ko) 2011-10-27 2015-02-27 케이스 웨스턴 리저브 유니버시티 초고도 농축된, 속효성 인슐린 유사체 제형
ES2670969T3 (es) 2012-11-13 2018-06-04 Adocia Formulación de acción rápida de insulina que comprende un compuesto aniónico sustituido
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
MY181626A (en) 2013-04-03 2020-12-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
US10137172B2 (en) 2013-04-30 2018-11-27 Novo Nordisk A/S Administration regime
AR098168A1 (es) * 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
KR20160104724A (ko) 2014-01-09 2016-09-05 사노피 인슐린 유사체 및/또는 인슐린 유도체의 안정화된 약제학적 제형
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN114939156A (zh) 2014-01-09 2022-08-26 赛诺菲 门冬胰岛素的稳定化药物制剂
AR099569A1 (es) 2014-02-28 2016-08-03 Novo Nordisk As Derivados de insulina y los usos médicos de estos
US10314911B2 (en) 2014-04-08 2019-06-11 Healthpartners Research & Education Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin
US9950039B2 (en) 2014-12-12 2018-04-24 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
AR102869A1 (es) 2014-12-16 2017-03-29 Lilly Co Eli Composiciones de insulina de rápida acción
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US20180244743A1 (en) 2015-08-25 2018-08-30 Novo Nordisk A/S Novel Insulin Derivatives and the Medical Uses Hereof
AU2016311283B2 (en) 2015-08-25 2020-10-08 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
EP3341401A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
JO3749B1 (ar) 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
CN105749292A (zh) * 2016-02-29 2016-07-13 苏州市贝克生物科技有限公司 促进胰岛素吸收的组合物及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3518893A1 (en) 2016-09-29 2019-08-07 Arecor Limited Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
KR20190140048A (ko) 2017-06-01 2019-12-18 일라이 릴리 앤드 캄파니 신속-작용 인슐린 조성물
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump for administering an insulin compound
CN112004521A (zh) 2018-04-04 2020-11-27 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵***
CN112040928A (zh) 2018-04-04 2020-12-04 艾瑞克有限公司 用于递送胰岛素化合物的医用输注泵***
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
FR3083700B1 (fr) * 2018-07-13 2021-03-12 Adocia Formulation thermostable d'insuline humaine a21g
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
EP4049032A1 (en) 2019-10-25 2022-08-31 Cercacor Laboratories, Inc. Indicator compounds, devices comprising indicator compounds, and methods of making and using the same
EP4073097A1 (en) 2019-12-11 2022-10-19 Novo Nordisk A/S Novel insulin analogues and uses thereof
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
US3758683A (en) * 1971-04-30 1973-09-11 R Jackson Insulin product
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
EP0018609B1 (de) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US4783441A (en) * 1979-04-30 1988-11-08 Hoechst Aktiengesellschaft Aqueous protein solutions stable to denaturation
JPS55153712A (en) 1979-05-18 1980-11-29 Kao Corp Insulin pharmaceutical preparation and its production
DE3033127A1 (de) 1980-09-03 1982-04-08 Hoechst Ag, 6000 Frankfurt Neue analoga des insulins
EP0083619A1 (en) 1981-07-17 1983-07-20 Nordisk Insulinlaboratorium A stable aqueous, therapeutic insulin preparation and a process for preparing it
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3327713A1 (de) 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Wasserloesliche disazoverbindungen, verfahren zu deren herstellung und ihre verwendung als farbstoffe
DE3327709A1 (de) * 1983-07-29 1985-02-07 Hoechst Ag, 6230 Frankfurt Insulin-derivat-kristallsuspensionen, verfahren zu deren herstellung und deren verwendung
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
CA1244347A (en) * 1984-05-29 1988-11-08 Eddie H. Massey Stabilized insulin formulations
ATE50502T1 (de) 1984-06-09 1990-03-15 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung.
KR860001166B1 (ko) * 1984-06-15 1986-08-20 곽성일 신발 결착용 구멍쇠의 제조방법
DE3440988A1 (de) * 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
DK113585D0 (da) 1985-03-12 1985-03-12 Novo Industri As Nye peptider
US5008241A (en) * 1985-03-12 1991-04-16 Novo Nordisk A/S Novel insulin peptides
DK347086D0 (da) 1986-07-21 1986-07-21 Novo Industri As Novel peptides
IL78425A (en) * 1985-04-15 1991-05-12 Lilly Co Eli Intranasal formulation containing insulin
DE3526995A1 (de) 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DE3541856A1 (de) 1985-11-27 1987-06-04 Hoechst Ag Eukaryotische fusionsproteine, ihre herstellung und verwendung sowie mittel zur durchfuehrung des verfahrens
US5496924A (en) 1985-11-27 1996-03-05 Hoechst Aktiengesellschaft Fusion protein comprising an interleukin-2 fragment ballast portion
CA1275922C (en) 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
DE3544295A1 (de) * 1985-12-14 1987-06-19 Bayer Ag Thermoplastische formmassen mit hoher kriechstromfestigkeit
PH23446A (en) * 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
CA1339416C (en) 1987-02-25 1997-09-02 Liselotte Langkjaer Insulin derivatives
US5034415A (en) * 1987-08-07 1991-07-23 Century Laboratories, Inc. Treatment of diabetes mellitus
DE3726655A1 (de) 1987-08-11 1989-02-23 Hoechst Ag Verfahren zur isolierung basischer proteine aus proteingemischen, welche solche basischen proteine enthalten
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE3827533A1 (de) * 1988-08-13 1990-02-15 Hoechst Ag Pharmazeutische zubereitung zur behandlung des diabetes mellitus
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
JPH04502465A (ja) 1988-12-23 1992-05-07 ノボ　ノルディスク　アクティーゼルスカブ ヒトインシュリン類似物質
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
PT93057B (pt) 1989-02-09 1995-12-29 Lilly Co Eli Processo para a preparacao de analogos da insulina
US5358857A (en) * 1989-08-29 1994-10-25 The General Hospital Corp. Method of preparing fusion proteins
JP3219096B2 (ja) * 1990-05-10 2001-10-15 ニコメド ファーマ エイエス ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
DK10191D0 (da) * 1991-01-22 1991-01-22 Novo Nordisk As Hidtil ukendte peptider
US6468959B1 (en) * 1991-12-05 2002-10-22 Alfatec-Pharm Gmbh Peroral dosage form for peptide containing medicaments, in particular insulin
AU671965B2 (en) * 1991-12-05 1996-09-19 Alfatec-Pharma Gmbh Pharmaceutically Applicable Nanosol and Process for Preparing The Same
US5614219A (en) * 1991-12-05 1997-03-25 Alfatec-Pharma Gmbh Oral administration form for peptide pharmaceutical substances, in particular insulin
DK0600372T3 (da) * 1992-12-02 1997-08-11 Hoechst Ag Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
HUT71583A (en) 1992-12-18 1995-12-28 Lilly Co Eli Insulin-analogs
DE4400709B4 (de) * 1993-01-13 2005-06-23 Denso Corp., Kariya Schraubenfestziehvorrichtung
US5606203A (en) * 1993-01-20 1997-02-25 Kabushiki Kaisha Toshiba Semiconductor device having Al-Cu wiring lines where Cu concentration is related to line width
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5559094A (en) * 1994-08-02 1996-09-24 Eli Lilly And Company AspB1 insulin analogs
BR9509201A (pt) 1994-09-09 1997-12-30 Takeda Chemical Industries Ltd Preparação de liberação sustemtada uso de um sal de metal polivalente insolúvel em água ou ligeiramente solúvel em água e processo para produzir uma preparação de liberação sustentada
US5547929A (en) * 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
US5707641A (en) 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
WO1996041606A2 (en) 1995-06-08 1996-12-27 Therexsys Limited Improved pharmaceutical compositions for gene therapy
EP0835101B1 (en) * 1995-06-27 2004-06-09 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
DE19545257A1 (de) * 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
DE19707245A1 (de) * 1997-02-25 1998-08-27 Patent Treuhand Ges Fuer Elektrische Gluehlampen Mbh Verfahren zur Herstellung einer elektrischen Glühlampe
US6310038B1 (en) * 1997-03-20 2001-10-30 Novo Nordisk A/S Pulmonary insulin crystals
IL131796A0 (en) * 1997-03-20 2001-03-19 Novo Nordisk As Zinc free insulin crystals for use in pulmonary compositions
US6043214A (en) * 1997-03-20 2000-03-28 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19726167B4 (de) * 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
ZA989744B (en) * 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
ES2230727T3 (es) 1997-11-12 2005-05-01 Alza Corporation Procedimiento de administracion dermal de polipeptidos.
ATE290877T1 (de) * 1998-01-09 2005-04-15 Novo Nordisk As Stabilisierte insulin-zubereitungen
UA65636C2 (uk) 1998-10-16 2004-04-15 Ново Нордіск А/С Стабільні концентровані препарати інсуліну для доставки через легені
US6211144B1 (en) * 1998-10-16 2001-04-03 Novo Nordisk A/S Stable concentrated insulin preparations for pulmonary delivery
US6635617B1 (en) * 1998-10-16 2003-10-21 Novo Nordisk A/S Insulin preparations for pulmonary delivery containing menthol
IL142002A0 (en) 1998-10-16 2002-03-10 Novo Nordisk As Insulin preparation for pulmonary delivery containing menthol
DE69914934T2 (de) 1998-11-18 2005-01-05 Novo Nordisk A/S Stabile, wässrige insulin-präparate ohne phenol und cresol
US6489292B1 (en) * 1998-11-18 2002-12-03 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol
DE19908041A1 (de) * 1999-02-24 2000-08-31 Hoecker Hartwig Kovalent verbrückte Insulindimere
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000074736A1 (en) * 1999-06-04 2000-12-14 Delrx Pharmaceutical Corporation Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
AU5760900A (en) 1999-06-25 2001-01-31 Minimed, Inc. Multiple agent diabetes therapy
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
KR100801588B1 (ko) * 1999-09-21 2008-02-05 스키에파마 캐나다 인코포레이티드 생물학적 유효 물질의 표면 변형된 미립자 조성물
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6734162B2 (en) * 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
AU2001264789A1 (en) 2000-06-08 2001-12-17 Eli Lilly And Company Protein powder for pulmonary delivery
KR100508695B1 (ko) 2001-02-13 2005-08-17 한국과학기술연구원 인슐린의 경구투여용 제형과 그의 제조방법
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
CN1160122C (zh) 2001-04-20 2004-08-04 清华大学 一种制备口服胰岛素油相制剂的方法
US20040265268A1 (en) * 2001-08-18 2004-12-30 Deepak Jain Compositions and methods for skin rejuvenation and repair
WO2003035051A2 (en) 2001-10-19 2003-05-01 Inhale Therapeutic Systems, Inc. The use of proton sequestering agents in drug formulations
US20050123509A1 (en) 2001-10-19 2005-06-09 Lehrman S. R. Modulating charge density to produce improvements in the characteristics of spray-dried proteins
US20060287221A1 (en) * 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia

Also Published As

Publication number Publication date
EP1381385B1 (de) 2011-02-09
SI1381385T1 (sl) 2011-05-31
KR20100061868A (ko) 2010-06-09
TWI301761B (en) 2008-10-11
JP4231292B2 (ja) 2009-02-25
CN1273187C (zh) 2006-09-06
EP1381385A1 (de) 2004-01-21
AR096376A2 (es) 2015-12-23
HUP0303596A3 (en) 2005-11-28
RU2003131187A (ru) 2005-03-10
US7452860B2 (en) 2008-11-18
US7205277B2 (en) 2007-04-17
PT2289539E (pt) 2012-11-20
DE10114178A1 (de) 2002-10-10
PE20020968A1 (es) 2002-12-10
US20030004096A1 (en) 2003-01-02
PT1381385E (pt) 2011-03-17
CY1113318T1 (el) 2016-04-13
MXPA03007942A (es) 2004-04-02
IL158057A0 (en) 2004-03-28
CN1498113A (zh) 2004-05-19
HU228847B1 (en) 2013-06-28
EP2289539A1 (de) 2011-03-02
AU2002302409B2 (en) 2007-01-04
NO20034125D0 (no) 2003-09-16
NO326780B1 (no) 2009-02-16
BRPI0208210B1 (pt) 2018-05-02
ME00408B (me) 2011-10-10
US7696162B2 (en) 2010-04-13
ZA200306637B (en) 2004-05-07
HRP20030765B1 (en) 2011-10-31
US20050187142A1 (en) 2005-08-25
CA2441260C (en) 2011-04-26
US20070155653A1 (en) 2007-07-05
DE50214903D1 (de) 2011-03-24
NO20034125L (no) 2003-11-11
US6960561B2 (en) 2005-11-01
WO2002076495A1 (de) 2002-10-03
KR20040011483A (ko) 2004-02-05
HRP20030765A2 (en) 2005-06-30
CY1111413T1 (el) 2015-08-05
DK1381385T3 (da) 2011-06-06
RS51579B (sr) 2011-08-31
US20050187143A1 (en) 2005-08-25
PL205465B1 (pl) 2010-04-30
CA2441260A1 (en) 2002-10-03
DK2289539T3 (da) 2013-01-14
MY129417A (en) 2007-03-30
MEP60808A (en) 2011-05-10
US7205276B2 (en) 2007-04-17
HUP0303596A2 (hu) 2004-01-28
PL362800A1 (en) 2004-11-02
IL158057A (en) 2013-10-31
ES2360505T3 (es) 2011-06-06
US20090186807A1 (en) 2009-07-23
BR0208210A (pt) 2004-03-09
YU73503A (sh) 2006-05-25
HK1061521A1 (en) 2004-09-24
KR100987311B1 (ko) 2010-10-13
JP2004523589A (ja) 2004-08-05
NZ528335A (en) 2005-03-24
ATE497777T1 (de) 2011-02-15
ES2393180T3 (es) 2012-12-19
EP2289539B1 (de) 2012-09-19
RU2311922C2 (ru) 2007-12-10
BRPI0208210B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
AR033059A1 (es) Preparados de insulina exentos de zinc y pobres en zinc, con estabilidad mejorada.
ECSP045496A (es) &#34;preparaciones acidas de insulina con estabilidad mejorada&#34;
AR030245A1 (es) Composiciones de gel que contienen metronidazol
ATE286057T1 (de) Pharmazeutische zubereitungen enthaltend clavulansäure
AR011611A1 (es) Composiciones en gel postespumante
BR0014486A (pt) Composições farmacêuticas contendo polipeptìdeo lìquido estabilizado
EA200300459A1 (ru) Новые, применяемые в качестве медикаментов антихолинергические средства, а также способ их получения
DE69418468D1 (de) Viskoelastische zusammensetzungen aus organischen fluorierten verbindungen
ATE99943T1 (de) Psychotropische wirkstoffe enthaltende stabilisierte loesungen.
AR025573A1 (es) Composicion laxante
AR025243A1 (es) Composicion liquida de pesticida.
DE69206976T2 (de) Viscose oberflächenaktive zusammensetzung
ATE289276T1 (de) Kanister enthaltend eine wirkstoff-formulierung mit fluorkohlenwasserstoff als treibmittel
DK1171124T3 (da) Anthelmintpræparater
DE50100314D1 (de) Mittel zur viruziden Händedesinfektion
DE60232271D1 (de) Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol-verbindungen
AR030647A1 (es) Composicion farmaceutica con actividad de agua especifica
SE9902742D0 (sv) New pharmaceutical formultion
RS50074B (sr) Farmaceutski preparat koji sadrži paracetamol i drotaverin
EA200400954A1 (ru) Фармацевтическая композиция, содержащая 2,2-дихлор-12-(4-хлорфенил)додекановую кислоту
ES2078727T3 (es) Composiciones farmaceuticas.
CL2015003221A1 (es) Formulacion farmaceutica estable para administracion intratecal que comprende una proteina arilsufatasa a (asa), sal y un tensoactivo de polisorbato y/o un agente amortiguador, y que ademas puede contener un agente estabilizante; contenedor que comprende dicha formulacion; uso para tratar la enfermedad leucodistrofia metacromatica (mld)
CY1114273T1 (el) Σταθεροποιημενα υγρα σκευασματα ιντερφερονης χωρις ανθρωπινη οροαλβουμινη
BR9904163A (pt) Integrador alimentar
ECSP003617A (es) Formulaciones ectoparasiticidas organicas topicas

Legal Events

Date Code Title Description
FC Refusal